Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686166 · ClinicalTrials.gov registry record · Phase 2
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT00686166 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 83 participants.
The verdict
NCT00686166, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying the side effects and how well giving oxaliplatin, capecitabine, and cetuximab together with radiation therapy followed by surgery works in treating patients with stage II or stage III rectal cancer.
Interventions
- DRUG oxaliplatin
- BIOLOGICAL cetuximab
- DRUG capecitabine
- RADIATION radiation therapy
- PROCEDURE therapeutic surgical procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2009-02 |
| Est. Completion | 2018-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00686166
The ClinicalTrials.gov registry entry for NCT00686166 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which oxaliplatin is the first listed.
NCT00686166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00686166 about?
NCT00686166 is a clinical study titled "S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer". RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the abi...
What is the current status of trial NCT00686166?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2009-02. Estimated completion is 2018-03.
What interventions are being tested in trial NCT00686166?
The interventions under investigation include: oxaliplatin (DRUG), cetuximab (BIOLOGICAL), capecitabine (DRUG), radiation therapy (RADIATION), therapeutic surgical procedure (PROCEDURE).
Who is sponsoring clinical trial NCT00686166?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.